Home | Medical-Newswire.Com:
(Medical-NewsWire.com, September 20, 2012 ) New York, NY -- Advanced Medical Isotope Corporation (ADMD) is already a US-based manufacturer and distributor of medical isotopes and is also developing key technologies that may offer a superior alternative to the current standard of care for battling cancer with nuclear medicine.
In a Thursday report, VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, identifies key point for optimism regarding the company and examines its speculative potential as an investment. Full report available at: http://vfcsstockhouse.com/blog/article/-advanced-medical-isotope-corporation-expanded-distribution-and-radiogel-technology-hold-the-keys-to-the-future
Advanced Medical Isotope Corporation (ADMD) has - through key partnerships, expanding distribution channels and the acquisition of a license to a novel cancer-fighting technology - well positioned itself to become a growth player in the field of nuclear medicine, specifically in the field of the production and distribution of medical isotopes. Medical isotopes are used in molecular imaging, therapy, and nuclear medicine to diagnose, manage and treat diseases and are deemed a hot item whenever discussed because of the geopolitical implications of non-nuclear nations attempt to enrich uranium for - ahem - solely medical purposes.
Advanced Medical is one of only a few companies in the United States manufacturing and distributing such isotopes and it's likely that business could quickly hit a growth spurt - not only through the company's own indigenous expansion and distribution efforts, but also because of the growing desire of the medical community in the US to use 'home grown' nuclear materials, not to mention increasing regulation that may force the community to do so anyway.
AMIC already offers a broad variety of isotopes and, as outlined in a recent quarterly report, is looking to expand its 'pipeline' of product offerings for its distribution network of customers that include - but is not limited to - national laboratories, hospitals, research facilities and universities.
Many of the company's isotopes are put to use through molecular imaging, or Positron Emission Tomography (PET), which enables Doctors and medical professionals to identify cancerous condictions well before detection means that search for tumor mass. Some of the radiopharmaceutical products based on the medical isotopes are also used in the early detection of certain cardiovascular indications and, as mentioned above, the demand for such products is growing, not shrinking. According to numbers identified in a recent company presentation and credited to the World Nuclear Association, the use of medical isotopes is growing at an annual rate of 10%.
That places AMIC right in the middle of a potential growth boom.
While production and distribution may encompass the company's core business model, AMIC is moving heavily into the field of treatment, too. The process of placing radioactive "seeds" in or near a cancerous tumor is known as brachytherapy, and AMIC is developing a pipeline based on such technology to augment the already-growing core business plan.
In April, the company acquired a license and numerous relating patents to an injectible radiogel technology that could have a significant impact on the next generation of fighting cancer. Using the radiogel technology doctors could deliver Yttrium-90 "microspheres" directly into cancerous tissue. Because the injectible polymer turns solid and holds the microspheres in place, there is little to no threat of any radiation escaping and damaging surrounding tissue. As described by Dr. Alan Walter, Chair of the AMIC Scientific Committee, in a presentation available on the company's home page, such a technology could be termed as using "smart bullets" to target cancerous cells.
Yttrium-90, in the form of Polymer seeds, is an already-established medical isotope with numerous applications in existing cancer treatment and has demonstrated effectiveness in combating head, neck, liver and prostate cancers, according to an above-linked company presentation. The radiogel application of Yttrium-90 could potentially 'storm the scene' in treating numerous cancer types with the intent of targeting those tumors in the hard-to-get to areas of the body that eliminates surgery as an option.
Both the Polymer seeds and the acquired the radiogel technology significantly boost the diversity of AMIC, offering a targeted path to enter the realm of caner treatment to augment the production, sales and distribution channels of its isotopes.
It's possible, based on previous expectations, that the Brachytherapy pipeline could hit market within a couple of years. At that point AMIC could either move forward with commercialization on its own or out-license the technology to someone else and use that revenue stream of royalties to fund the expansion of the core business.
Shares were up by eight percent on Wednesday, although volume was very light. That said, volume has been picking up significantly over the past few months and has tripled already once this year. Volume has also stormed in after the company's more relevant press releases, indicating that there are investors on the sidelines who either wait to play a quick trade or may be taking a 'wait and see' approach to playing this still-speculative stock.
Should the potential of the AMIC distribution network continue to expand and meet the growing demand for nuclear medicine - and should the polymer seeds and radiogel technology also hit market with momentum - then it's likely that the current ADMD share price could start to move. Currently, shares consistently trade for a few pennies above the twenty cents mark, give or take.
Based on the potential of the developing technology, already-available products and future product offerings, the current ADMD trading levels could serve as an opportune accumulation period to those looking at the risk/reward profile for the future. The current market cap of still under twenty million indicates that many investors are still unconvinced, but when searching for potential payoff picks on the bulletin board stocks, it pays off to be in while the stock is still moving along relatively unnoticed, as the best percentage gains to be had in any run start with being in place before the run starts.
That said, the stock market is risky business and there are no sure things, that's why it's up to each investor to conduct his or her own DD and invest accordingly.
Still a developing story worth monitoring.
Disclosure: No position.
Follow ADMD developments and other small cap stocks at VFCsStockHouse.com
Contact VFC's Stock House: email@example.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks, biopharma stocks, and pharmaceutical and healthcare stocks. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights and opinions into broader-market news. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and make informed and well thought-out investment decisions. For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on
top health stories.
Rights activists protest award for ex-Montana judge who blamed victim of rape
29 May 2015 at 8:07pm
A small group of women's rights activists rallied in Montana on Friday to protest a lifetime achievement award for a state judge censured for suggesting that a 14-year-old girl was partly to blame for her rape by a teacher. More than two dozen protesters led by the Montana chapter of the National Organization for Women attended the candlelight vigil outside the Yellowstone Art Museum in Billings where former state District Judge G. Todd Baugh was to be given the annual award by a local bar association, said Marian Bradley, regional NOW head.
Kansas hospital monitoring patient for possible Ebola infection
29 May 2015 at 5:43pm
The University of Kansas Hospital said on Friday it was monitoring a patient for a possible Ebola infection after he returned from the West African nation of Sierra Leone and developed a fever. "The patient is extremely low risk. It's just the fever that tipped the balance," Dr. Lee Norman at University of Kansas Hospital in Kansas City, Kansas, told a news conference.
U.S. military orders review as anthrax mishap widens
29 May 2015 at 5:26pm
By Phil Stewart WASHINGTON (Reuters) - The U.S. military said on Friday it discovered even more suspected shipments of live anthrax than previously thought, both in the United States and abroad, and ordered a sweeping review of practices meant to inactivate the bacteria. The Pentagon said a total of 11 states, two more than it first acknowledged, received "suspect samples," as did Australia and South Korea. It had previously only identified a foreign shipment to a U.S. air base south of Seoul.
Pentagon: Anthrax shipments broader than first thought
29 May 2015 at 4:07pm
WASHINGTON (AP) ? The Pentagon said Friday that the Army's mistaken shipments of live anthrax to research laboratories were more widespread than it initially reported, prompting the Defense Department's second-ranking official to order a thorough review.
U.S. military orders broad review as anthrax mishap widens
29 May 2015 at 3:39pm
WASHINGTON (Reuters) - The U.S. military said on Friday it discovered even more suspected cases of inadvertent shipments of live anthrax than previously thought, both in the United States and abroad, and ordered a sweeping review of its practices for inactivating samples. "As of now, 24 laboratories in 11 states and two foreign countries are believed to have received suspect samples," the Pentagon said in a statement. (Reporting by Phil Stewart; Editing by Sandra Maler)
Zimmerman gets GPS protection from Florida shooter
29 May 2015 at 3:29pm
A Florida man who this month fired a shot at George Zimmerman, the man acquitted of murder in the 2012 death of an unarmed black teenager, was ordered on Friday to wear a GPS tracking device to warn of possible future attacks, according to local news reports of the court hearing. Matthew Apperson, 36, was charged with aggravated assault with a deadly weapon, shooting into a vehicle and aggravated battery with a deadly weapon after an encounter with Zimmerman on a road in Lake Mary, central Florida, on May 11. In a motion asking for the GPS requirement, prosecutors said Apperson has a history of mental illness including bipolar disorder and general anxiety disorder.
Genetic glitch can predict response to new class of cancer drugs
29 May 2015 at 2:59pm
By Julie Steenhuysen CHICAGO (Reuters) - Patients with colon and other cancers who have a specific defect in genes needed for DNA repair are far more likely to respond to a new class of drugs such as Merck & Co's Keytruda, which enlist the immune system to attack tumors, a new study has shown. The small study, financed not by Big Pharma but by swimmers who raised charitable donations, tested Keytruda in patients with advanced colon and rectal cancers and found 92 percent of patients with the genetic defect had their disease controlled compared with 16 percent who did not carry the defect. The findings, announced on Friday at the American Society of Clinical Oncology (ASCO) meeting in Chicago, point to a new way to predict who will respond to the treatments, which are known as PD-1 inhibitors and can cost $150,000 a year.
Obesity increases risk for common heart rhythm disorder
29 May 2015 at 2:57pm
By Lisa Rapaport (Reuters Health) - Obesity increases the risk for atrial fibrillation, a common heart rhythm disorder that can lead to blood clots, stroke and heart failure, a new analysis suggests. Researchers reviewed data from 51 previously published studies covering more than 600,000 people and found that obesity also made it more likely that patients with atrial fibrillation would have complications after surgery to treat the condition. ?A lower risk of developing heart rhythm disorders such as atrial fibrillation can be added to the list of health benefits from weight reduction,? senior study author Dr. Prashanthan Sanders, director of the center for heart rhythm disorders at the University of Adelaide in Australia, said by email.
U.S. bird flu outbreak in poultry
29 May 2015 at 2:51pm
(Reuters) - The United States is dealing with its worst outbreak of bird flu on record. More than 44 million chickens, turkeys and other birds have been culled since last December. This is not the same avian influenza virus that has caused human infections in Africa, Asia and Europe. Migrating birds are believed to be responsible for some of the virus' spread and researchers are still studying how it is reaching poultry farms. In the current outbreak, the U.S. Department of Agriculture has confirmed bird flu in commercial and backyard flocks in 16 states so far. ...
5 Ways to Build Awareness This Summer
29 May 2015 at 2:45pm
Recently I accomplished a goal that I've been trying to achieve for a long while - I finally got certified to be a yoga teacher. I went to a studio and went through a 12 week long yoga immersion. I was so happy with the wide variety of knowledge and experience that this process gave to me, but this is only just the beginning of my yoga journey....
With no peace, Ukraine is beset by humanitarian risks: U.N.
29 May 2015 at 2:21pm
By Tom Miles GENEVA (Reuters) - Ukraine's flawed ceasefire has left pensioners, infants and women mired in a humanitarian crisis that could get rapidly better or rapidly worse, the U.N.'s top representative in the country said in an interview on Friday. A Feb. 12 Minsk ceasefire agreement was "not really working", with hundreds of shelling incidents every day, said Neal Walker, U.N. resident coordinator in Ukraine. "Very clearly, you have a huge humanitarian risk if the conflict escalates," Walker told Reuters.
Bristol's Opdivo cuts risk of lung cancer death for some
29 May 2015 at 1:39pm
By Deena Beasley Chicago (Reuters) - Bristol-Myers Squibb Co's drug, Opdivo, improved survival in a trial of patients with the most common form of lung cancer, but it did not work in patients who tested negative for a specific protein in their tumors, leading to a nearly 7 percent sell-off in the company's shares on Friday. The Phase III trial found that Opdivo, part of a new class of drugs that harness the immune system to fight cancer, reduced by 27 percent the risk of death from advanced non-squamous non-small cell lung cancer (NSCLC), compared with chemotherapy.
People may drink more than they realize
29 May 2015 at 1:22pm
In England, surveys measuring everyday alcohol consumption account for only 60 percent of the total alcohol sold in stores, the researchers write in BMC Medicine. By only focusing on typical drinking patterns, surveys miss a lot of alcohol consumption that happens on special occasions like weddings, holidays, and sporting events, according to Mark Bellis, the lead author on the study. The researchers conducted a phone survey of over 6,000 people over the age of 16 in England to assess the amount of special occasion drinking that may not be picked up by other surveys.
More cancer success with drugs that enlist immune system
29 May 2015 at 1:21pm
CHICAGO (AP) ? For the first time, a major study shows that a drug targeting the body's disease-fighting immune system may improve survival for the most common form of lung cancer.
Mom Receives Gift of Life From Son's Unexpected Death
29 May 2015 at 1:03pm
Rose Perry received her son's kidney in a transplant after the 24-year-old died from a stroke.